Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen Clinical research trials and Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen. Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen clinical trial. Participants frequently obtain the most expert healthcare available for their Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.

Home > "I" Clinical Trials Conditions > Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen

Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen



Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen

For Condition: Melanoma,Neoplasm Metastasis
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This is a study of a melanoma tumor antigen DNA vaccine. Plasmid DNA encoding the T cell antigen gp100 will be administered to patients with metastatic melanoma. Patients will receive DNA injections every 4 weeks for up to 4 doses. The study is designed to evaluate the potential therapeutic role, immunologic effects and toxicity of repeated doses of this DNA vaccine administered either alone or in conjunction with the cytokine adjuvant, IL-2. Immune reactivity to the DNA vaccine will be monitored in all patients by analysis of melanoma-specific T cell precursors prior to and after immunization.
Details: This is a study of a melanoma tumor antigen DNA vaccine. Plasmid DNA encoding the T cell antigen gp100 will be administered to patients with metastatic melanoma. Patients will receive DNA injections every 4 weeks for up to 4 doses. The study is designed to evaluate the potential therapeutic role, immunologic effects and toxicity of repeated doses of this DNA vaccine administered either alone or in conjunction with the cytokine adjuvant, IL-2. Immune reactivity to the DNA vaccine will be monitored in all patients by analysis of melanoma-specific T cell precursors prior to and after immunization.
Eligibility:
Study Type:  Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Any patient age greater than or equal to 16 with measurable metastatic melanoma who has failed standard treatment and has an expected survival of greater than three months will be considered. Serum creatinine of 2.0 mg/dl or less; Bilirubin 1.6 mg/dl or less; WBC 3000/mm(3) or greater; Platelet count 90,000 mm(3) or greater; Serum AST/ALT less than two times normal; ECOG performance status of 0 or 1. Patients of both genders must be willing to practice effective birth control during this trial. EXCLUSION CRITERIA: Patients will be excluded: Who are undergoing or have undergone in the past 3 weeks any other form of therapy except surgery for their cancer; Have active systemic infections, coagulation disorders, autoimmune disease or other major medical illnesses of the cardiovascular or respiratory systems or any known immunodeficiency disease; Who require steroid therapy; Who are pregnant; Who are known to be positive for hepatitis BsAG or HIV antibody; Who have any form of primary or secondary immunodeficiency.
Total Enrollment: 65

Location and Contact Information:

National Cancer Institute (NCI)
Bethesda,  Maryland,  20892
United States
 


Additional Information:
Study ID Numbers:  980086;  98-C-0086
Study Start Date: March 28, 1998
Record last reviewed: July 8, 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001692

Other Neoplasm Metastasis Studies:
1. Immunization of Patients with Metastatic Melanoma Using Recombinant Fowlpox Virus Encoding a gp100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

2. Immunization of Patients with Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

3. Treatment of Patients with Metastatic Melanoma Using Cloned Peripheral Blood Lymphocytes Sensitized In Vitro to the gp209-2M Immunodominant Peptide

4. Liver Perfusion of Melphalan in Inoperable Liver Cancer

5. Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine

Related Studies:

Other Neoplasm Metastasis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials

Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen
Modify your Search

  Other Neoplasm Metastasis Clinical Trials
  Other Maryland Clinical Trials
  Other Bethesda Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103